Amgen Inc. $AMGN Shares Sold by Atlas Private Wealth Advisors

Atlas Private Wealth Advisors lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 51.3% in the third quarter, Holdings Channel.com reports. The institutional investor owned 2,397 shares of the medical research company’s stock after selling 2,525 shares during the quarter. Atlas Private Wealth Advisors’ holdings in Amgen were worth $677,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Brighton Jones LLC raised its stake in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares during the period. Sivia Capital Partners LLC grew its holdings in Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares in the last quarter. Pure Financial Advisors LLC increased its stake in Amgen by 15.6% during the 2nd quarter. Pure Financial Advisors LLC now owns 4,822 shares of the medical research company’s stock worth $1,346,000 after buying an additional 652 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Amgen by 11.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 543,933 shares of the medical research company’s stock worth $151,872,000 after buying an additional 56,183 shares in the last quarter. Finally, Triad Wealth Partners LLC purchased a new position in Amgen in the 2nd quarter valued at about $206,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 10,908 shares of company stock valued at $3,674,966 in the last ninety days. Company insiders own 0.76% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of analyst reports. Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a research report on Friday, December 5th. Sanford C. Bernstein downgraded Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective on the stock. in a report on Tuesday, January 20th. Cantor Fitzgerald upped their target price on Amgen from $305.00 to $315.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Scotiabank started coverage on shares of Amgen in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price target for the company. Finally, HSBC restated a “buy” rating and issued a $425.00 price target on shares of Amgen in a research note on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $342.45.

Amgen Trading Down 0.3%

Shares of NASDAQ AMGN opened at $341.88 on Friday. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $353.25. The company has a market cap of $184.10 billion, a price-to-earnings ratio of 26.42, a price-to-earnings-growth ratio of 3.02 and a beta of 0.45. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. The stock’s 50 day simple moving average is $332.60 and its 200 day simple moving average is $309.22.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. The firm had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The firm’s revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the business earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a $2.52 dividend. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a yield of 2.9%. This is a boost from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is 73.57%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.